Analysts think CLRB stock price could increase by 520%
Jul 31, 2024, 6:26 AM
2.80%
What does CLRB do
Cellectar Biosciences, Inc., based in Florham Park, New Jersey, specializes in developing phospholipid drug conjugates (PDCs) for cancer treatment and imaging, with a product pipeline that includes iopofosine targeting multiple myeloma and pediatric cancers. Founded in 2005, the company employs 15 people and focuses on cancer-targeting treatments through its PDC delivery platform, pursuing development both independently and via collaborations.
6 analysts think CLRB stock price will increase by 519.63%. The current median analyst target is $13.26 compared to a current stock price of $2.14. The lowest analysts target is $7.07 and the highest analyst target is $29.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
